181 related articles for article (PubMed ID: 38427289)
1. Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection: A Multicenter Observational Study.
Rebold N; Alosaimy S; Pearson JC; Dionne B; Taqi A; Lagnf A; Lucas K; Biagi M; Lombardo N; Eudy J; Anderson DT; Mahoney MV; Kufel WD; D'Antonio JA; Jones BM; Frens JJ; Baumeister T; Geriak M; Sakoulas G; Farmakiotis D; Delaportas D; Larew J; Veve MP; Rybak MJ
Infect Dis Ther; 2024 Mar; 13(3):565-579. PubMed ID: 38427289
[TBL] [Abstract][Full Text] [Related]
2. DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci.
Hidalgo-Tenorio C; Vinuesa D; Plata A; Martin Dávila P; Iftimie S; Sequera S; Loeches B; Lopez-Cortés LE; Fariñas MC; Fernández-Roldan C; Javier-Martinez R; Muñoz P; Arenas-Miras MDM; Martínez-Marcos FJ; Miró JM; Herrero C; Bereciartua E; De Jesus SE; Pasquau J
Ann Clin Microbiol Antimicrob; 2019 Oct; 18(1):30. PubMed ID: 31629409
[TBL] [Abstract][Full Text] [Related]
3. Oritavancin as sequential therapy for Gram-positive bloodstream infections.
Texidor WM; Miller MA; Molina KC; Krsak M; Calvert B; Hart C; Storer M; Fish DN
BMC Infect Dis; 2024 Jan; 24(1):127. PubMed ID: 38267844
[TBL] [Abstract][Full Text] [Related]
4. Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections.
Veve MP; Patel N; Smith ZA; Yeager SD; Wright LR; Shorman MA
Int J Antimicrob Agents; 2020 Dec; 56(6):106210. PubMed ID: 33223119
[TBL] [Abstract][Full Text] [Related]
5. Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials.
Gonzalez PL; Rappo U; Akinapelli K; McGregor JS; Puttagunta S; Dunne MW
Infect Dis Ther; 2022 Feb; 11(1):423-434. PubMed ID: 34905144
[TBL] [Abstract][Full Text] [Related]
6. Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections.
Bork JT; Heil EL; Berry S; Lopes E; Davé R; Gilliam BL; Amoroso A
Infect Dis Ther; 2019 Jun; 8(2):171-184. PubMed ID: 31054088
[TBL] [Abstract][Full Text] [Related]
7. Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial.
Turner NA; Zaharoff S; King H; Evans S; Hamasaki T; Lodise T; Ghazaryan V; Beresnev T; Riccobene T; Patel R; Doernberg SB; Rappo U; Fowler VG; Holland TL;
Trials; 2022 May; 23(1):407. PubMed ID: 35578360
[TBL] [Abstract][Full Text] [Related]
8. Dalbavancin as sequential therapy for infective endocarditis due to Gram-positive organisms: a review.
Fazili T; Bansal E; Garner D; Gomez M; Stornelli N
Int J Antimicrob Agents; 2023 Apr; 61(4):106749. PubMed ID: 36758775
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Dalbavancin Use on Clinical Outcomes, Cost-Savings, and Adherence at a Large Safety Net Hospital.
Lueking R; Wei W; Mang NS; Ortwine JK; Meisner J
Microbiol Spectr; 2023 Feb; 11(1):e0238522. PubMed ID: 36537818
[TBL] [Abstract][Full Text] [Related]
10. Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004).
Jones RN; Stilwell MG; Sader HS; Fritsche TR; Goldstein BP
Diagn Microbiol Infect Dis; 2006 Feb; 54(2):149-53. PubMed ID: 16426793
[TBL] [Abstract][Full Text] [Related]
11. Dalbavancin as an alternative to traditional outpatient parenteral antimicrobial therapy for deep gram-positive infections - an observational, retrospective review.
Bao H; Igwilo-Alaneme R; Sonia F; Cowman K; Kahn M; Nori P
Ther Adv Infect Dis; 2024; 11():20499361241245523. PubMed ID: 38645297
[TBL] [Abstract][Full Text] [Related]
12. Dalbavancin as consolidation antibiotic treatment in infective endocarditis, cardiac implantable electronic devices infection and bacteremia: Clinical experience of 7 years.
Salinas-Botrán A; Olmos-Blanco C; Fernández de Velasco-Pérez D; Guzmán-Carreras A; Morales-Rosas A; Gómez-Ramírez D
Enferm Infecc Microbiol Clin (Engl Ed); 2024 May; ():. PubMed ID: 38763866
[TBL] [Abstract][Full Text] [Related]
13. Substance use disorder-associated infections' treatment with dalbavancin enabling outpatient transition (SUDDEN OUT) - an investigator-initiated single-arm unblinded prospective cohort study.
Krsak M; Scherger S; Miller MA; Cobb V; Montague BT; Henao-Martínez AF; Molina KC
Ther Adv Infect Dis; 2024; 11():20499361231223889. PubMed ID: 38249543
[TBL] [Abstract][Full Text] [Related]
14. Real-World Data Regarding Dalbavancin Use before and during the COVID-19 Pandemic-A Single-Center Retrospective Study.
Ioannou P; Wolff N; Mathioudaki A; Spanias C; Spernovasilis N; Kofteridis DP
Antibiotics (Basel); 2023 Jul; 12(7):. PubMed ID: 37508301
[TBL] [Abstract][Full Text] [Related]
15. Successful use of dalbavancin in the treatment of gram positive blood stream infections: a case series.
Evins C; Lancaster H; Schnee AE
Ann Clin Microbiol Antimicrob; 2022 Apr; 21(1):16. PubMed ID: 35473711
[TBL] [Abstract][Full Text] [Related]
16. Use of dalbavancin in infective endocarditis: a case series.
Guleri A; More R; Sharma R; Wong M; Abdelrahman A
JAC Antimicrob Resist; 2021 Sep; 3(3):dlab099. PubMed ID: 34396119
[TBL] [Abstract][Full Text] [Related]
17. Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection.
Tobudic S; Forstner C; Burgmann H; Lagler H; Steininger C; Traby L; Vossen MG; Winkler S; Thalhammer F
Infection; 2019 Dec; 47(6):1013-1020. PubMed ID: 31520397
[TBL] [Abstract][Full Text] [Related]
18. French national cohort of first use of dalbavancin: A high proportion of off-label use.
Dinh A; Duran C; Pavese P; Khatchatourian L; Monnin B; Bleibtreu A; Denis E; Etienne C; Rouanes N; Mahieu R; Bouchand F; Davido B; Lotte R; Cabaret P; Camou F; Chavanet P; Assi A; Limonta S; Lechiche C; Riou R; Courjon J; Illes G; Lacassin-Beller F; Senneville E;
Int J Antimicrob Agents; 2019 Nov; 54(5):668-672. PubMed ID: 31400471
[TBL] [Abstract][Full Text] [Related]
19. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.
Zhanel GG; Calic D; Schweizer F; Zelenitsky S; Adam H; Lagacé-Wiens PR; Rubinstein E; Gin AS; Hoban DJ; Karlowsky JA
Drugs; 2010 May; 70(7):859-86. PubMed ID: 20426497
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Sequential Dalbavancin With Standard-of-Care Treatment for
Molina KC; Lunowa C; Lebin M; Segerstrom Nunez A; Azimi SF; Krsak M; Mueller SW; Miller MA
Open Forum Infect Dis; 2022 Jul; 9(7):ofac335. PubMed ID: 35899276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
